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tions, miscarriage, fetal growth restriction 
and preeclampsia are a spectrum of disorders 
sharing overlapping clinical and pathological 
features. All are associated with thrombotic 
pathogenic processes, ranging from micro-
vascular fibrin deposition in the glomerular 
vessels in preeclampsia, to placental infarc-
tion in fetal growth restriction. However, a 
number of disease mechanisms contribute 
to these outcomes, and it is not clear how 
critical the thrombotic process is across the 
various components of the spectrum of dis-
ease and between pregnancies. Some predic-
tive and risk factors are known, but the only 
established preventative measures that exist 
are antithrombotic agents – low-dose aspirin 
and low-molecular-weight heparin. How-
ever, their efficacy is modest. This approach 
assumes that antithrombotic processes will 
impact on the disease outcome, yet the con-
tribution of thrombosis may be highly vari-
able. The benefits of intervention with anti-
thrombotic agents may be best seen in those 
women where thrombosis is a major factor 
in the pathophysiology. Identifying those 
women most likely to benefit from treatment 
would allow stratification of treatment based 
on disease process, which in turn may pro-
vide more effective use of interventions. Such 
a stratified or precision medicine approach is 
already widely used in cancer care, where the 
direction of oncological research has moved 
away from analysis of treatment response in 
cohorts sharing the same diagnosis based on 
the organ affected and tumor histology, to 
treatment based on biomarkers specific to 
the molecular pathology of the tumor. It may 
now be time for obstetrics to adopt such a 
personalized medicine approach. However, 
this requires a biomarker with clinical utility 
to guide treatment. Recent research suggests 
that ANXA5 may be such a biomarker.
Placenta-mediated pregnancy 
complications
The placenta-mediated pregnancy compli-
cations, noted above, constitute a spectrum 
of relatively common yet enigmatic obstet-
ric disorders. They share similar, but by no 
means the same, prothrombotic factors and 
have a placental origin. However, these are 
multifactorial conditions where a number of 
pathological processes, other than thrombo-
sis, have been identified. The contribution of 
these processes is variably expressed across 
the spectrum of disease and between affected 
pregnancies. Therefore, interventions focused 
on a single possible disease mechanism would 
only be anticipated to be effective where that 
mechanism plays a dominant or major role. 
Applying an intervention without stratifying 
by pathological mechanism may underlie the 
lack of consistency between different inter-
vention trials in conditions where more than 
one process may result in the same final out-
come. Miscarriage is a good example of this 
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as the same outcome may result for a large number of 
different pathological processes of which a thrombotic 
mechanism is only one.
Recurrent miscarriage is a serious health issue, which 
has a significant impact on women’s quality of life. 
It is defined as three or more consecutive early preg-
nancy losses. Although multiple etiologies are known, 
and genetic components play a significant role, half of 
cases are not associated with any of the known risk fac-
tors [1]. Currently no single predictive biomarker has 
been identified to guide treatment. Antithrombotic 
interventions in unselected patients have generally not 
been shown to be effective [2–5].
Preeclampsia is a common and serious obstetric dis-
order with multifactorial pathophysiology [6] focused 
on endothelial damage, microthrombosis, vasocon-
striction and oxidative stress. There is a genetic com-
ponent, however, the relative weight of maternal and 
placental genetic factors in susceptibility remains 
unclear [7]. Preeclampsia has multiple phenotypic vari-
ants, including preterm and term onset, which each 
likely represent different genetic architectures [8].
Fetal growth restriction is the reduction in fetal 
growth velocity leading to failure of the fetus to 
achieve its genetic growth potential. It is associated 
with significant perinatal mortality and morbidity [9] 
and occurs in 3–7% of pregnancies [10]. Genetic com-
ponents are known to play a significant etiological 
role [11]; however, the most common underlying cause 
is placental insufficiency with substantial overlap with 
the features seen in preeclampsia, including placental 
thrombosis and infarction. This highlights thrombo-
genic processes as potential risk factors. Intervention 
with low-dose aspirin has a limited effect likely due to 
the heterogeneity of the disease process, however, given 
its prevalence and unfavorable fetal outcomes, risk 
stratification is highly desirable for better more specific 
treatment, but is not available due in part to lack of 
appropriate biomarkers.
ANXA5
ANXA5 is a protein with anticoagulant functions. 
Although dispersed throughout the body, ANXA5 is 
highly expressed on the apical surfaces of the syncytio-
trophoblast, where it lines the placental villi at the mater-
nal–fetal circulation interface and is integral to placental 
thrombomodulatory function [12–14]. It prolongs phos-
pholipid-dependent coagulation reactions by displacing 
coagulant proteins from phospholipid surfaces [14].
Expression of the protein has been considered in 
placenta-mediated pregnancy complications, because 
thrombosis and placental dysfunction are key fea-
tures of their pathogeneses. Theoretically, low levels 
of this anticoagulant in the placenta would reduce 
the ‘shielding’ of phospholipids, thereby facilitating 
phospholipid-dependent coagulation activation with 
risk of thrombosis and placental infarction [15]. Of 
interest is the expression of ANXA5, which varies 
by the haplotype of the ANXA5 gene. M2 is a com-
mon haplotype, giving rise to low levels of circulat-
ing ANXA5 protein [6]. Recently it has been reported 
that the prevalence of the M2 haplotype is increased 
in women with placenta-mediated pregnancy 
complications [16].
The origin of ANXA5 protein in placental villi is 
either maternal circulation, trophoblastic production 
or a combination of both [6]. Placental expression will 
be dependent on both maternal and paternal genetic 
contributions. Therefore this may constitute a mech-
anism for the paternal contribution to the disease 
process and may offer an explanation for change in 
paternity being a risk factor for preeclampsia [17–19].
There is growing evidence of the ANXA5 M2 hap-
lotype being associated with placenta-mediated preg-
nancy complications including preeclampsia [6], fetal 
growth restriction [20] and recurrent pregnancy loss 
[15,16], although not all studies are consistent [13]. How-
ever, the maternal and paternal M2 haplotype status 
might offer the opportunity to provide a biomarker for 
pregnancies at risk of placental thrombosis and there-
fore allow antithrombotic treatment to be stratified 
based on the parental haplotype status.
Future perspective
We have few biomarkers available in pregnancy for 
placenta-mediated pregnancy complications. Further 
as the placenta is key to the disease process, a specific 
biomarker reflecting the risk of placental thrombosis 
(rather than solely that of the mother) may be of value 
in stratifying disease. Thus, determining parental M2 
haplotype status provides a novel opportunity to explore 
whether this could be an important biomarker to guide 
treatment. Further, with increasing availability of cell-
free fetal DNA testing, noninvasive prenatal identifica-
tion of high-risk patients may be based directly on the 
placental genotype. Such stratification of those at risk 
of placental thrombosis offers the opportunity to bring 
a stratified medicine approach to obstetrics allowing 
better targeting for antithrombotic interventions, in 
particular on groups with homogeneous pathological 
mechanisms.
“Such stratification of those at risk of placental 
thrombosis offers the opportunity to bring 
a stratified medicine approach to obstetrics 
allowing better targeting for antithrombotic 
interventions, in particular on groups with 
homogeneous pathological mechanisms.”
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